Unknown

Dataset Information

0

De novo Drug Delivery Modalities for Treating Damaged Hearts: Current Challenges and Emerging Solutions.

ABSTRACT: Cardiovascular disease (CVD) is the leading cause of mortality, resulting in approximately one-third of deaths worldwide. Among CVD, acute myocardial infarctions (MI) is the leading cause of death. Current treatment modalities for treating CVD have improved over the years, but the demand for new and innovative therapies has been on the rise. The field of nanomedicine and nanotechnology has opened a new paradigm for treating damaged hearts by providing improved drug delivery methods, specifically targeting injured areas of the myocardium. With the advent of innovative biomaterials, newer therapeutics such as growth factors, stem cells, and exosomes have been successfully delivered to the injured myocardial tissue, promoting improvement in cardiac function. This review focuses on three major drug delivery modalities: nanoparticles, microspheres, and hydrogels, and their potential for treating damaged hearts following an MI.

SUBMITTER: Alvi SB 

PROVIDER: S-EPMC8505729 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

<i>De novo</i> Drug Delivery Modalities for Treating Damaged Hearts: Current Challenges and Emerging Solutions.

Alvi Syed Baseeruddin SB   Ahmed Salmman S   Sridharan Divya D   Naseer Zahra Z   Pracha Nooruddin N   Wang Henry H   Boudoulas Konstantinos Dean KD   Zhu Wuqiang W   Sayed Nazish N   Khan Mahmood M  

Frontiers in cardiovascular medicine 20210928

Cardiovascular disease (CVD) is the leading cause of mortality, resulting in approximately one-third of deaths worldwide. Among CVD, acute myocardial infarctions (MI) is the leading cause of death. Current treatment modalities for treating CVD have improved over the years, but the demand for new and innovative therapies has been on the rise. The field of nanomedicine and nanotechnology has opened a new paradigm for treating damaged hearts by providing improved drug delivery methods, specifically  ...[more]

Similar Datasets

Unknown Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions.
| S-EPMC3337775 | biostudies-literature
Unknown Energy functions in de novo protein design: current challenges and future prospects.
| S-EPMC3851009 | biostudies-literature
Unknown A Comprehensive Study of De Novo Genome Assemblers: Current Challenges and Future Prospective.
| S-EPMC5826002 | biostudies-literature
Unknown Current and emerging treatment modalities for spinocerebellar ataxias.
| S-EPMC9048095 | biostudies-literature
Unknown Current Challenges and Opportunities in Treating Glioblastoma.
| S-EPMC5907910 | biostudies-literature
Unknown Healing Chronic Wounds: Current Challenges and Potential Solutions.
| S-EPMC6585977 | biostudies-literature
Unknown Incorporation of sensing modalities into de novo designed fluorescence-activating proteins.
| S-EPMC7870846 | biostudies-literature
Unknown Current and emerging modalities for detection of cardiotoxicity in cardio-oncology.
| S-EPMC5558528 | biostudies-other
Unknown Radiotheranostics in oncology: current challenges and emerging opportunities.
| S-EPMC10585450 | biostudies-literature
Unknown Huanglongbing Pandemic: Current Challenges and Emerging Management Strategies.
| S-EPMC9824665 | biostudies-literature